PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
Open Access
- 27 March 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 10 (2), R27
- https://doi.org/10.1186/bcr1984
Abstract
In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer. Tumor DNA from 140 patients with stage II–III breast cancer undergoing neoadjuvant chemotherapy was sequenced for PIK3CA mutations on exons 1, 9, and 20. Mutation status was correlated with clinical/pathological parameters and chemotherapy response as (a) pathological complete response (pCR) versus residual cancer or (b) quantitative residual cancer burden (RCB) scores, including stratification for estrogen receptor (ER) expression status, type of chemotherapy, and by exons. Twenty-three patients (16.4%) harbored a PIK3CA mutation, with 12, 11, and 0 mutations located in exons 9, 20, and 1, respectively. PIK3CA exon 9 mutations were more frequent among node-negative (52% versus 25%; P = 0.012) than node-positive tumors, particularly among ER-positive tumors. pCR rates and RCB scores were similar among patients with the wild-type and mutant PIK3CA genes, even after stratification by ER status, chemotherapy regimen (anthracycline versus anthracycline plus paclitaxel), or exon. PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors. In this study, PIK3CA mutation was associated with a decreased rate of node-positive disease, particularly among ER-positive tumors.Keywords
This publication has 28 references indexed in Scilit:
- Evaluation of biological pathways involved in chemotherapy response in breast cancerBreast Cancer Research, 2008
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell LinesMolecular Cancer Research, 2007
- Point mutations of protein kinases and individualised cancer therapyExpert Opinion on Pharmacotherapy, 2006
- Intranuclear 3′-phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis?Cellular Signalling, 2006
- Frequent Mutation of the PIK3CA Gene in Ovarian and Breast CancersClinical Cancer Research, 2005
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001